HomeTopics › Essential Tremor

Essential Tremor

GMJ News knowledge hub · last reviewed August 2026 · Georgian Medical Journal

SummaryStatisticsGlossaryGMJ newsFAQDocumentsOrganizationsResearch

Essential tremor (ET) — the most common movement disorder globally — affects approximately 70-90 million people worldwide (approximately 1% of the global population, rising to 4-5% in adults over 65), causing embarrassing, disabling action tremor of the hands and arms (and sometimes head, voice and legs) that interferes with writing, eating, drinking and daily activities (WHO). Despite being far more common than Parkinson's disease, essential tremor receives a fraction of the research attention and public awareness. Treatment options: propranolol and primidone (first-line); for severe medication-refractory tremor: deep brain stimulation (DBS) or MR-guided focused ultrasound (MRgFUS) — approved by FDA in 2016 as a non-invasive neurosurgical option.

Key messages

70-90 million people — most common movement disorder
Essential tremor (ET) affects approximately 70-90 million people globally (approximately 1% of the global population; 4-5% over age 65) — making it the most common movement disorder worldwide, far exceeding Parkinson's disease in prevalence (WHO).
Action tremor — not resting
ET causes action tremor (worst during voluntary movement — writing, holding a glass, eating) rather than resting tremor (characteristic of Parkinson's). This distinction is critical for diagnosis: resting tremor that improves with movement is Parkinson's; tremor that worsens with movement is ET.
Propranolol and primidone first-line
Propranolol (beta-blocker) and primidone (anticonvulsant) are first-line pharmacological treatments for ET — each reducing tremor amplitude by approximately 50-60% in responders, but neither achieves complete control and approximately 30% of patients respond inadequately.
MRgFUS — non-invasive surgery
MR-guided focused ultrasound (MRgFUS/Exablate) — FDA approved in 2016 — uses focused ultrasound waves to create a precise lesion in the thalamic VIM nucleus without any incision or radiation, offering immediate, durable tremor control (approximately 70-80% improvement) for medication-refractory ET.
Deep brain stimulation for severe cases
Deep brain stimulation (DBS) of the ventral intermediate (VIM) thalamic nucleus is the gold-standard neurosurgical treatment for severe, medication-refractory ET — providing approximately 80-90% tremor reduction. Unlike thalamotomy, DBS is adjustable and reversible.
Underdiagnosed and undertreated
ET is significantly underdiagnosed — often dismissed as "just getting old" or anxiety-related shaking. Many patients report decades of functional disability, social embarrassment and withdrawal from activities before receiving a diagnosis and treatment.

Key statistics

70-90M
people with essential tremor globally
WHO
~1%
global prevalence; 4-5% in over-65s
WHO/research
50-60%
tremor reduction with propranolol or primidone
WHO/Cochrane
70-80%
tremor improvement with MRgFUS (FDA 2016)
FDA/NEJM
2016
year MRgFUS FDA-approved for ET
FDA
Decades
average time from symptom onset to diagnosis (if ever)
ET Foundation

Essential tremor prevalence by age group (%) — WHO/published meta-analyses

Source: WHO. ET prevalence rises steeply with age — a growing challenge with global ageing.

Glossary of key terms

Action tremor
WHO/Clinical
Tremor occurring during voluntary movement or posture maintenance — divided into: postural tremor (limb maintained against gravity); kinetic tremor (during movement — including intention tremor, which worsens approaching a target); and task-specific tremor (writing, voice). ET predominantly causes postural and kinetic tremor.
VIM nucleus (ventral intermediate)
WHO/Neurosurgery
A thalamic nucleus in the ventrolateral thalamus — receiving inputs from the cerebellum and projecting to the motor cortex. The critical node in the tremor circuit. Targeted by thalamotomy (lesion), DBS (stimulation) and MRgFUS (thermal lesion) for tremor suppression.
MRgFUS (MR-guided Focused Ultrasound)
FDA 2016
A non-invasive neurosurgical technique — 1,000+ ultrasound beams focused through the skull to create a precise thermal lesion in the VIM nucleus of the thalamus. Done under MRI guidance, without incision or radiation. FDA-approved for ET (2016) and unilateral Parkinson's tremor (2018). Immediate effect; approximately 70-80% tremor improvement.
DBS (Deep Brain Stimulation)
FDA/ESTN
Implantable brain stimulator — electrodes placed in the VIM thalamic nucleus deliver high-frequency electrical stimulation that suppresses tremor. Advantages: adjustable (stimulation parameters can be changed), reversible, bilateral possible. Approximately 80-90% tremor reduction. Requires surgery; battery replacement every 3-5 years.
Propranolol
WHO EML
A non-selective beta-adrenergic blocker — the most-studied first-line ET medication. Reduces tremor amplitude by approximately 50% in responders. Dose: 60-320mg/day (long-acting formulation preferred). Contraindications: asthma, significant bradycardia, cardiac block, Raynaud's. On WHO Essential Medicines List.
Primidone
WHO EML
An anticonvulsant (converted to phenobarbital and phenylethylmalonamide in the liver) — equally effective to propranolol for ET, with similar evidence base. Start at low dose (12.5-25mg at night) to reduce acute sedation side effects. Particularly useful when beta-blockers are contraindicated.

Latest GMJ coverage

AI-Guided Ultrasound Predicts Bubble Collapse to Improve Brain Barrier Opening
09/07/2026
Third Electrode Pair Improves Deep Brain Stimulation Precision in Mouse Study
29/06/2026
Australian Hospital Deploys World-First Robotic Surgery Technology for Complex Procedures
07/08/2026
Magnesium Deficiency Linked to Multiple Chronic Diseases: What the Evidence Shows
02/08/2026

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Parkinson's diseaseMND/neurologicalMS (tremor)AgeingDisabilityDepression/anxiety (ET impact)

About this hub. Produced by the GMJ News Editorial Team as a public-good service. Every statistic is linked to its primary source. Documents are preserved in the GMJ Repository with full attribution. Georgian Medical Journal · Contact the editorial team
GMJ BriefsView all →